ERACAL
EraCal Therapeutics is a Swiss biotech company committed to cutting-edge science and medicine. EraCal develops drugs to treat different diseases.
ERACAL
Industry:
Biotechnology Pharmaceutical
Founded:
2017-01-01
Address:
Zürich, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.eracal.ch
Total Employee:
1+
Status:
Active
Total Funding:
1.14 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Euro Google Apps For Business GStatic Google Static Content Google Cloud Sectigo SSL
Similar Organizations
Celsius Therapeutics
Celsius Therapeutics is a biotechnology company that develops precision medicines for cancer and autoimmune disease patients.
Hependo
Hependo develops drugs to treat hepatitis C.
Medella Therapeutics Ltd.
Medella Therapeutics Ltd. develops monoclonal antibody drugs to stop cancer tumor growth.
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Current Advisors List
Current Employees Featured
Founder
Investors List
Redalpine
Redalpine investment in Seed Round - EraCal
Life Sciences Fund
Life Sciences Fund investment in Seed Round - EraCal
Bernina BioInvest
Bernina BioInvest investment in Seed Round - EraCal
Life Sciences Fund
Life Sciences Fund investment in Seed Round - EraCal
Venture Kick
Venture Kick investment in Pre Seed Round - EraCal
Venture Kick
Venture Kick investment in Grant - EraCal
Venture Kick
Venture Kick investment in Grant - EraCal
Official Site Inspections
http://www.eracal.ch
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.171
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "EraCal"
Company | EraCal Therapeutics
The biotech-company EraCal Therapeutics Ltd. is a spin-off from the University of Zurich and Harvard University. The company is privately held by a biotech-specialized investor base. ...See details»
EraCal Therapeutics
Eracal Therapeutics Ltd. develops first-in-class drugs to treat obesity and its comorbidities.See details»
EraCal - Crunchbase Company Profile & Funding
EraCal's platform supports large-scale, unbiased drug discovery, focusing on identifying novel mechanisms for first-in-class drugs. Era-107 A lead appetite suppressor developed by EraCal, …See details»
EraCal Therapeutics AG - Venture Kick
Jan 23, 2024 EraCal Therapeutics AG: Excess weight and obesity are among the most widespread health risks globally. EraCal fights it: the University of Zurich and Harvard …See details»
Science - EraCal Therapeutics
EraCal’s platform enables unbiased and large-scale drug discovery. The journal Science Advances published part of EraCal’s translational proof of concept. Such phenotypic strategies …See details»
EraCal Therapeutics 2025 Company Profile: Valuation, …
EraCal Therapeutics General Information Description. Developer of drugs in-vivo screening platform designed to treat metabolic syndrome with medical advancement. The company's platform develops drugs including identified …See details»
EraCal Therapeutics AG - Zefix
CH-ID: CH-020-3046515-0: FRC-ID: 1365236: cantonal excerpt - Opens in a new tab. Handelsregisteramt des Kantons Basel-Stadt . ... EraCal Therapeutics AG, in Basel, CHE …See details»
EraCal Therapeutics Ltd – Swiss Biotech
EraCal Therapeutics Ltd. develops a oral-active anti-obesity drug, a first-in-class appetite suppressor. This new chemical entity emerged from EraCal’s drug discovery platform, which also forms the basis of a research collaboration with …See details»
EraCal Therapeutics - VentureRadar
EraCal’s platform enables unbiased and large-scale in vivo drug discovery in zebrafish larvae. The journal Science Advances published part of EraCal’s translational proof of concept. Such …See details»
EraCal Therapeutics enters agreement with Novo …
Jan 23, 2024 EraCal participated in Venture Leaders Life Sciences in 2020, won the last stage of Venture Kick in 2019, and was ranked among the TOP 100 Swiss Startups from 2020 to 2023. ... ORGANIZATION. Transforming …See details»
EraCal Therapeutics AG - top100startup.ch
Feb 16, 2023 01.02.2021 EraCal expands operations and moves to larger laboratories on the 5th floor at Wagistrasse 13, Schlieren. 09.09.2020 EraCal is among Switzerland's Most …See details»
100% Scientist, In Vivo Molecular Mechanism - Campus Career
CEO Josua Jordi Ph.D. [email protected] 24.10.2019 www.eracal.ch - non-confidential - Page 1 of 1 100% Scientist, In Vivo Molecular Mechanism Location: Zurich Schlieren, as soon …See details»
Novartis and Zurich University Invest CHF 1 Million in Appetite ...
Apr 6, 2019 EraCal Therapeutics AG is developing a safer, more-potent anti-obesity pill to disrupt a $77-billion-market. ... ORGANIZATION. Transforming scientific innovation into …See details»
EraCal Therapeutics AG - Drug pipelines, Patents, Clinical trials
Explore EraCal Therapeutics AG with its drug pipeline, therapeutic area, technology platform, 14 news, Disease Domain:Endocrinology and Metabolic Disease, Technology Platform:Small …See details»
Howtofightobesityandother metabolic disorders—swimmingly
Www.eracal.ch Howtofightobesityandother metabolic disorders—swimmingly EraCal Therapeutics is developing a novel oral-active anti-obesity drug, Era-379, identified using the company’s …See details»
EraCal Therapeutics AG - Venturelab
Jan 10, 2018 EraCal fights it: the University of Zurich and Harvard University spin-off, founded in 2018, develops novel appetite suppressants to combat obesity. Reducing appetite facilitates …See details»
EraCal and Nestlé Health Science team up to develop new …
Feb 16, 2023 Today, Eracal and Nestlé Health Science announced a collaboration to develop new neutraceuticals that help control food intake. We talked to EraCal CEO Josua Jordi about …See details»
Novo Nordisk to invest €235 million in EraCal - startupticker.ch
Jan 23, 2024 Ann Clare Kessler, chairman of EraCal Therapeutics, said, “Novo Nordisk is the perfect partner to assess EraCal’s molecules that we believe have a unique mechanism for …See details»
EraCal Therapeutics AG - startup.ch
EraCal Therapeutics AG: Excess weight and obesity are among the most widespread health risks globally. EraCal fights it: the University of Zurich and Harvard University spin-off, founded in …See details»
EraCal aims to raise CHF 15m Series A in 2021: the advisor
May 12, 2020 EraCal, a Swiss biotech developing an anti-obesity drug, aims to raise CHF 15m in a Series A round next year, according to Mergermarket who spoke with its CEO. The funds …See details»